Literature DB >> 10454161

Glial cell line-derived neurotrophic factor protects dopaminergic neurons from 6-hydroxydopamine toxicity in vitro.

K Eggert1, J Schlegel, W Oertel, C Würz, J C Krieg, H Vedder.   

Abstract

Glial cell line-derived neurotrophic factor (GDNF) is a potent and specific neurotrophic factor for dopaminergic neurons. GDNF has been previously shown to protect dopaminergic neurons from lesion-induced degeneration in vivo. In this study we investigated the effect of GDNF on 6-hydroxydopamine (6-OHDA)-treated dopaminergic neurons in vitro. In dissociated cultures of embryonic rat mesencephalon, 6-OHDA exhibited a dose-dependent cytotoxicity on tyrosine hydroxylase (TH)-immunoreactive neurons. After pre-treatment with GDNF, however, 6-OHDA-induced loss of dopaminergic neurons was effectively reduced. It has been shown recently that GDNF signals through the receptor tyrosine kinase Ret and the GDNF receptor-alpha (GFR-alpha). By RT-PCR, we found both Ret- and GFR-alpha-genes to be expressed in the cultured mesencephalic cells. We propose that the neuroprotective effect of GDNF on 6-OHDA-treated dopaminergic neurons in vitro is most likely mediated by functional Ret receptor signaling pathways.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10454161     DOI: 10.1016/s0304-3940(99)00443-7

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

1.  Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease.

Authors:  S M Kulich; C T Chu
Journal:  J Neurochem       Date:  2001-05       Impact factor: 5.372

Review 2.  Current Neurogenic and Neuroprotective Strategies to Prevent and Treat Neurodegenerative and Neuropsychiatric Disorders.

Authors:  I M Carvalho; P B Coelho; P C Costa; C S Marques; R S Oliveira; D C Ferreira
Journal:  Neuromolecular Med       Date:  2015-09-15       Impact factor: 3.843

Review 3.  NURR1 in Parkinson disease--from pathogenesis to therapeutic potential.

Authors:  Mickael Decressac; Nikolaos Volakakis; Anders Björklund; Thomas Perlmann
Journal:  Nat Rev Neurol       Date:  2013-10-15       Impact factor: 42.937

Review 4.  Roles for the TGFβ superfamily in the development and survival of midbrain dopaminergic neurons.

Authors:  Shane V Hegarty; Aideen M Sullivan; Gerard W O'Keeffe
Journal:  Mol Neurobiol       Date:  2014-02-07       Impact factor: 5.590

Review 5.  Challenges and promises in the development of neurotrophic factor-based therapies for Parkinson's disease.

Authors:  Tiago Martins Rodrigues; André Jerónimo-Santos; Tiago Fleming Outeiro; Ana Maria Sebastião; Maria José Diógenes
Journal:  Drugs Aging       Date:  2014-04       Impact factor: 3.923

6.  Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease.

Authors:  Enara Herrán; Catalina Requejo; Jose Angel Ruiz-Ortega; Asier Aristieta; Manoli Igartua; Harkaitz Bengoetxea; Luisa Ugedo; Jose Luis Pedraz; Jose Vicente Lafuente; Rosa Maria Hernández
Journal:  Int J Nanomedicine       Date:  2014-05-27

Review 7.  Neurotrophic factors: from neurodevelopmental regulators to novel therapies for Parkinson's disease.

Authors:  Shane V Hegarty; Gerard W O'Keeffe; Aideen M Sullivan
Journal:  Neural Regen Res       Date:  2014-10-01       Impact factor: 5.135

Review 8.  Current Experimental Studies of Gene Therapy in Parkinson's Disease.

Authors:  Jing-Ya Lin; Cheng-Long Xie; Su-Fang Zhang; Weien Yuan; Zhen-Guo Liu
Journal:  Front Aging Neurosci       Date:  2017-05-03       Impact factor: 5.750

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.